Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in OncologyOpen Access

Risk factors for recurrence and bleeding in colorectal cancer patients with cancer-associated venous thrombembolism

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhikun LiangJMJun MaoJXJingwen Xie

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies recurrence and bleeding risk factors in colorectal cancer patients, suggesting significant survival implications.

Key Points

  • Independent risk factors for recurrent venous thromboembolism include age, history of VTE, and ECOG performance status.
  • Major bleeding risk factors include age, history of major bleeding, ECOG score, and antiplatelet therapy, highlighting key patient vulnerabilities.
  • Successful identification of risk factors aids in survival predictions, with adverse events significantly lowering one-year survival rates.
  • Cancer stage and recent major surgery impact recurrence and bleeding risks, emphasizing clinical decision-making for patient management.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68c1d24654b1d3bfb60f8492https://doi.org/10.3389/fonc.2025.1648003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival Implications of Thrombus Recurrence or Bleeding in Cancer Patients Receiving Anticoagulation for Venous Thromboembolism Treatment2022 · 24 citations
  2. 2Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism2010 · 471 citations
  3. 3Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial2021 · 33 citations
  4. 4Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials2020 · 116 citations
  5. 5Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer2021 · 57 citations